Efficacy of Single-Pill Perindopril/Indapamide in Patients with Hypertension and Type 2 Diabetes

  title={Efficacy of Single-Pill Perindopril/Indapamide in Patients with Hypertension and Type 2 Diabetes},
  author={T. A. Netchessova and A. P. Shepelkevich and T. V. Gorbat and on behalf of the Novara Atherosclerosis Study group},
  journal={High Blood Pressure \& Cardiovascular Prevention},
ObjectiveHypertension and type 2 diabetes in combination are associated with a significantly higher level of cardiovascular events. The aim of this prospective study was to evaluate the antihypertensive efficacy and tolerability of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.Design and MethodsPatients with both hypertension and type 2 diabetes were enrolled in this multicenter, prospective, open clinical study. Single-pill perindopril/indapamide was… 

Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study

Switching to PER/IND at full dose was well tolerated, leading to fast BP reduction and control in the majority of patients with uncontrolled hypertension, including difficult-to-treat patients with diabetes.

Antihypertensive Effectiveness of Perindopril Arginine and Indapamide Single-Pill Combination According to Body Mass Index: Findings from the FORSAGE Study

  • M. GlezerE. A. E. E. M. N. O. S. I. V. E. D. E. V. A. A. N. S. Sebko Popova Gaponova Doronina Dvornikova Oleyniko O. M. Rogozina
  • Medicine
    Cardiology and Therapy
  • 2020
In subjects with uncontrolled BP on existing antihypertensive therapy, switching to perindopril arginine/indapamide SPC was associated with statistically significant decreases in BP and higher rates of target BP achievement in all BMI groups, including more than 70% of overweight and obese patients.

Erratum to: Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study

Evaluated efficacy and safety of single-pill combination perindopril/indapamide at full dose (10/2.5 mg) in hypertensive patients, including diabetics, with BP uncontrolled by previous medication.

Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes

Treatment with perindopril/indapamide has microvascular and macrovascular effects that extend beyond blood pressure lowering and that this treatment might confer a long-lasting beneficial vascular legacy.

Which thiazide to choose as add-on therapy for hypertension?

Combined therapy is required in the majority of patients with hypertension to achieve blood pressure (BP) targets. Although different antihypertensive drugs can be combined, not all combinations are

Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA)

Some aspects to consider when choosing treatments in the economic context of Latin-America for promoting the most efficient use of resources in a scarce environment and to provide quality information to decision makers to formulate safe, cost-effective, and patient-centered health policies are provided.



Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease.

The treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline.

Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice

Outpatients with primary hypertension who did not reach the blood pressure goal with antihypertensive treatment were enrolled if their treating physician had planned to switch them to fixed-dose perindopril 10 mg/indapamide 2.5 mg.

Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy

Indapamide, because of its well-documented beneficial effects on cardiovascular and renal outcomes, represents a safe and valuable option for treating patients with high BP, and there is, however, still room for new trials evaluating the combination of this diuretic with other types of antihypertensive drugs, in particular a calcium antagonist such as amlodipine.

Treatment of hypertension in patients 80 years of age or older.

The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial.

Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression

De-novo microalbuminuria was more frequent in those patients presenting with established cardiovascular disease and predicts the future development of cardiovascular events but was not accompanied by a significant worsening of renal function, indicating that a reappraisal of renin–angiotensin–aldosterone system (RAAS) suppression is required when micro Albuminuria appears in patients under chronic RAAS suppression.

A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients.

Renal disease is highly prevalent in people with type 2 diabetes, and co-existence with hypertension increases the risk of cardiac events and mortality. Despite many large randomized trials,

Kidney protection: a key target in the management of patients with diabetes

  • L. RuilopeJ. Segura
  • Medicine, Biology
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 2009
Treatment with the perindopril/indapamide fixed combination on top of contemporary cardiovascular care prevents one renal event in 20 patients with type 2 diabetes treated over 5 years, adding to the reduction in total and cardiovascular mortality in the main ADVANCE trial.

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

High albuminuria and low eGFR are independent risk factors for cardiovascular and renal events among patients with type 2 diabetes, according to the ADVANCE study.

K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

The purpose of the Executive Summary is to provide a "stand-alone" summary of the background, scope, methods, and key recommendations, as well as the complete text of the guideline statements.